帕金森病中的α-synuclein:与抑郁症的融合的中心点
Ayesha M Yusuf1,2, Burcu Yener Ilce1, Hamid A Alhaj1,2
1Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
NPJ Parkinson's disease
|November 20, 2025
概括
帕金森病 (PD) 和抑郁症共享的重叠途径是由α-synuclein聚合驱动的. 这表明抑郁症可能作为PD诊断和进展的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 精神病学是一个精神病学.
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病.
- 抑郁症是PD中常见的并发症,使其严重程度恶化.
- 阿尔法-同核素聚合是PD的关键病理标志.
研究的目的:
- 审查PD和抑郁症之间的机制协同作用,以α-synuclein为中心.
- 使用基因组和转录组数据识别融合基因和通路.
- 探索抑郁症作为PD生物标志物的潜力.
主要方法:
- 文献审查侧重于α-synuclein的作用.
- 现有基因组和转录基因组数据集的二次分析.
- 识别重叠的分子通路.
主要成果:
- 阿尔法同核素聚合将PD病理与抑郁机制联系起来.
- 在PD和抑郁症之间确定了融合的基因和途径.
- 共享的路径突出显示了潜在的生物联系.
结论:
- 阿尔法-同核素聚合是PD和抑郁症之间的机制性联系的核心.
- 抑郁症可能成为诊断PD和监测PD进展的宝贵生物标志物.
- 对共享途径的进一步研究可能会揭示新的治疗点.
相关概念视频
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Treatment
953
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
953
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K


